TMEM163 acts as a tumor-suppressive gene in LUAD; higher expression correlates with reduced mortality risk and is part of a four-gene signature (HLF–CHRDL1–SELENBP1–TMEM163) that robustly predicts better OS across four independent LUAD cohorts [139]. The gene discussed is TMEM163; the disease is neoplasm.